After the tolerability and efficacy of ALK inhibitors were demonstrated in adults with ALK‐rearranged non‐small cell lung cancer, these drugs were consecutively tested in clinical trials or compassionate use programmes in children, adolescents and adults with ALCL46, 72, 73, 74, 75, 76, 79, 80 (Table 3). The gene discussed is ALK; the disease is lung cancer.